We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Home » JANSSEN PHARMACEUTICA ANNOUNCES COLLABORATION WITH VERTEX PHARMACEUTICALS TO DEVELOP AND COMMERCIALIZE VX-950 FOR TREATMENT OF HEPATITIS C
JANSSEN PHARMACEUTICA ANNOUNCES COLLABORATION WITH VERTEX PHARMACEUTICALS TO DEVELOP AND COMMERCIALIZE VX-950 FOR TREATMENT OF HEPATITIS C
June 30, 2006
Johnson & Johnson announced today that Janssen
Pharmaceutica N.V., a Johnson & Johnson company, has entered into a collaboration
with Vertex Pharmaceuticals Incorporated to develop and commercialize Vertex's
investigational hepatitis C virus (HCV) protease inhibitor, VX-950.
Finanzen.net (http://finanzen.net/news/news_detail.asp?NewsNr=410842)
